Contribution of Systemic and Somatic Factors to Clinical Response and Resistance in Urothelial Cancer

Request Access

Biomarkers (2)

  • Albumin less than 4 - Albumin less than 4 g/dL at treatment start (phv00405248.v1.p1)
  • Hb less than 10 - Hemoglobin less than 10 g/dL at treatment start (phv00405247.v1.p1)

Demographics (2)

Disease Events (16)

  • Alive Status - Alive at the time of final chart review (phv00405253.v1.p1)
  • Best OR - Best response per RECIST 1.1 (phv00405249.v1.p1)
  • IS_TUMOR - Tumor status (phv00405258.v1.p1)
  • Liver Mets - Liver metastases present at treatment start (phv00405244.v1.p1)
  • Ongoing Responder - Ongoing responder per RECIST 1.1 at the time of final chart review (phv00405250.v1.p1)
  • OS - Overall survival (phv00405254.v1.p1)
  • PD-L1 IC Score - The PD-L1 tumor-infiltrating immune cell (IC) status defined by the percentage of PD-L1 positive ICs in the tumor microenvironment by immunohistochemistry using the SP142 assay (Ventana, AZ, USA) (phv00405236.v1.p1)
  • Perioperative chemo_POD within 12 months - Previous perioperative chemotherapy, with first progression within 12 months (phv00405240.v1.p1)
  • PFS - Progression free survival per RECIST 1.1 (phv00405252.v1.p1)
  • PRIMARY_METASTATIC_TUMOR - Primary tumor or metastasis (phv00405259.v1.p1)
  • PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00405261.v1.p1)
  • Prior BCG - History of prior intravesical BCG treatment (phv00405238.v1.p1)
  • Prior Lines - Number of previous systemic regimens in the metastatic setting (phv00405239.v1.p1)
  • Still on Treatment - Still on study therapy at the time of final chart review (phv00405251.v1.p1)
  • TFLC less than 3mo - Time from last chemotherapy less than 3 months (phv00405245.v1.p1)
  • Visceral Mets - Visceral metastases presents at treatment start (phv00405243.v1.p1)

Substance Use (1)

Other (16)